Induction of cell cycle arrest in human MCF-7 breast cancer cells by cis-stilbene derivatives related to VIOXX®

Toxicology Letters

Volumn 186, Issue 2, 2009, Pages 115-122

  Sangjun, Sunisa ^a,b   de Jong, Esther ^b   Nijmeijer, Sandra ^b   Mutarapat, Thumnoon ^c   Ruchirawat, Somsak ^c   van den Berg, Martin ^b   van Duursen, Majorie B M ^b  

^a ASIAN INSTITUTE OF TECHNOLOGY   (Thailand)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Toxicology and Management of Chemicals   (Thailand)

Author keywords

Breast cancer; Cell cycle; Chemoprevention; Stilbene derivatives; Structure activity relationship

Indexed keywords

3 (2,4 DIFLUOROPHENYL) 4 (4 METHYLSULFONYLPHENYL) 5H FURAN 2 ONE; 3 (2,4 DIFLUOROPHENYL) 4 (4 METHYLSULFYLPHENYL) 5H FURAN 2 ONE; 3 (3,4 DIFLUOROPHENYL) 4 (4 METHYLSULFONYLPHENYL) 5H FURAN 2 ONE; 3 (3,4 DIFLUOROPHENYL) 4 (4 METHYLSULFYLPHENYL) 5H FURAN 2 ONE; 3 (3,4 DIMETHOXYPHENYL) 4 (3,4,5 TRIMETHOXYPHENYL) 5H FURAN 2 ONE; 3 (3,4 DIMETHOXYPHENYL) 4 (METHOXYPHENYL) 5H FURAN 2 ONE; 3 (3,4 DIMETHOXYPHENYL) 4 PHENYL 5H FURAN 2 ONE; 3,4 BIS (3,4 DIMETHOXYPHENYL) 5H FURAN 2 ONE; 3,4 BIS (4 METHOXYPHENYL) 5H FURAN 2 ONE; 3,4 DIPHENYL 5H FURAN 2 ONE; 4 (4 METHOXYPHENYL) 3 PHENYL 5H FURAN 2 ONE; 4 (4 METHYLSULFYLPHENYL) 3 PHENYL 5H FURAN 2 ONE; RESVERATROL; ROFECOXIB; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CHEMOPROPHYLAXIS; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; FLOW CYTOMETRY; HUMANS; LACTONES; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 61549120430     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.01.017     Document Type: Article

References (54)

1. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., and Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24 (2004) 2783-2840
2. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006) 1397-1421
3. Alkhalaf M. Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation. Eur. J. Cancer Prev. 16 (2007) 334-341
4. Arun B., and Hortobagyi G.N. Progress in breast cancer chemoprevention. Endocr. Rel. Cancer 9 (2002) 15-32
5. Aziz M.H., Kumar R., and Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int. J. Oncol. 23 (2003) 17-28
6. Bhat K.P., Lantvit D., Christov K., Mehta R.G., Moon R.C., and Pezzuto J.M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61 (2001) 7456-7463
7. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., and Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141 (2000) 3657-3667
8. Bray F., McCarron P., and Parkin D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 6 (2004) 229-239
9. Cao T.M., Durrant D., Tripathi A., Liu J., Tsai S., Kellogg G.E., Simoni D., and Lee R.M. Stilbene derivatives that are colchicine-site microtubule inhibitors have antileukemic activity and minimal systemic toxicity. Am. J. Hematol. 83 (2008) 390-397
10. Cassidy A., Hanley B., and Lamuela Raventos R.M. Isoflavones, lignans and stilbenes--origins, metabolism and potential importance to human health. J. Sci. Food Agric. 80 (2000) 1044-1062
11. Denizot F., and Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89 (1986) 271-277
12. Dikshit D.K., Singh S., Singh M.M., and Kamboj V.P. Synthesis and biological activity of 2,3- and 3,4-diarylfurans and 2,3,4-triaryl-2,5-furans. Indian J. Chem. B 29B (1990) 954-960
13. Dorai T., and Aggarwal B.B. Role of chemopreventive agents in cancer therapy. Cancer Lett. 215 (2004) 129-140
14. Durrant D., Corwin F., Simoni D., Zhao M., Rudek M.A., Salloum F.N., Kukreja R.C., Fatouros P.P., and Lee R.M. cis-3, 4′,5-Trimethoxy-3′-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion. Cancer Chemother. Pharmacol. (2008)
15. Durrant D., Richards J.E., Walker W.T., Baker K.A., Simoni D., and Lee R.M. Mechanism of cell death induced by cis-3, 4′, 5-trimethoxy-3′-aminostilbene in ovarian cancer. Gynecol. Oncol. (2008)
16. Fresco P., Borges F., Diniz C., and Marques M.P. New insights on the anticancer properties of dietary polyphenols. Med. Res. Rev. 26 (2006) 747-766
17. Gali-Muhtasib H., and Bakkar N. Modulating cell cycle: current applications and prospects for future drug development. Curr. Cancer Drug Targets 2 (2002) 309-336
18. Gamet-Payrastre L., Li P., Lumeau S., Cassar G., Dupont M.A., Chevolleau S., Gasc N., Tulliez J., and Terce F. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 60 (2000) 1426-1433
19. Goss P.E., and Strasser-Weippl K. Aromatase inhibitors for chemoprevention. Best Pract. Res. Clin. Endocrinol. Metab. 18 (2004) 113-130
20. Greenwald P. Cancer chemoprevention. BMJ 324 (2002) 714-718
21. Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr. Rel. Cancer 15 (2008) 73-90
22. Hodges-Gallagher L., Valentine C.D., El Bader S., and Kushner P.J. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res. Treat. 109 (2008) 241-250
23. Hsieh T.C., Burfeind P., Laud K., Backer J.M., Traganos F., Darzynkiewicz Z., and Wu J.M. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int. J. Oncol. 15 (1999) 245-252
24. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., and Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
25. Kaufmann D., Pojarova M., Vogel S., Liebl R., Gastpar R., Gross D., Nishino T., Pfaller T., and von Angerer E. Antimitotic activities of 2-phenylindole-3-carbaldehydes in human breast cancer cells. Bioorg. Med. Chem. 15 (2007) 5122-5136
26. Kelloff G.J., Crowell J.A., Steele V.E., Lubet R.A., Malone W.A., Boone C.W., Kopelovich L., Hawk E.T., Lieberman R., Lawrence J.A., Ali I., Viner J.L., and Sigman C.C. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J. Nutr. 130 (2000) 467S-471S
27. Kim Y., Nam N.H., You Y.J., and Ahn B.Z. Synthesis and cytotoxicity of 3,4-diaryl-2(5H)-furanones. Bioorg. Med. Chem. Lett. 12 (2002) 719-722
28. Kim Y.A., Choi B.T., Lee Y.T., Park D.I., Rhee S.H., Park K.Y., and Choi Y.H. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol. Rep. 11 (2004) 441-446
29. Le Corre L., Chalabi N., Delort L., Bignon Y.J., and Bernard-Gallon D.J. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol. Nutr. Food Res. 49 (2005) 462-471
30. Lee E.J., Min H.Y., Joo Park H., Chung H.J., Kim S., Nam Han Y., and Lee S.K. G2/M cell cycle arrest and induction of apoptosis by a stilbenoid, 3,4,5-trimethoxy-4′-bromo-cis-stilbene, in human lung cancer cells. Life Sci. 75 (2004) 2829-2839
31. Lu R., and Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell Physiol. 179 (1999) 297-304
32. Manson M.M., Gescher A., Hudson E.A., Plummer S.M., Squires M.S., and Prigent S.A. Blocking and suppressing mechanisms of chemoprevention by dietary constituents. Toxicol. Lett. 112-113 (2000) 499-505
33. Matsuoka A., Takeshita K., Furuta A., Ozaki M., Fukuhara K., and Miyata N. The 4′-hydroxy group is responsible for the in vitro cytogenetic activity of resveratrol. Mutat. Res. 521 (2002) 29-35
34. Mgbonyebi O.P., Russo J., and Russo I.H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol. 12 (1998) 865-869
35. Osborne C.K., Zhao H., and Fuqua S.A. Selective estrogen receptor modulators: structure, function, and clinical use. J. Clin. Oncol. 18 (2000) 3172-3186
36. Park H., Aiyar S.E., Fan P., Wang J., Yue W., Okouneva T., Cox C., Jordan M.A., Demers L., Cho H., Kim S., Song R.X., and Santen R.J. Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. Cancer Res. 67 (2007) 5717-5726
37. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000: the global picture. Eur. J. Cancer 37 Suppl. 8 (2001) S4-S66
38. Pirali T., Busacca S., Beltrami L., Imovilli D., Pagliai F., Miglio G., Massarotti A., Verotta L., Tron G.C., Sorba G., and Genazzani A.A. Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents. J. Med. Chem. 49 (2006) 5372-5376
39. Pozo-Guisado E., Alvarez-Barrientos A., Mulero-Navarro S., Santiago-Josefat B., and Fernandez-Salguero P.M. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem. Pharmacol. 64 (2002) 1375-1386
40. Quan H., Xu Y., and Lou L. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrup ting agent combretastatin A4. Int. J. Cancer 122 (2008) 1730-1737
41. Sarkar F.H., and Li Y.W. Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol. Sin. 28 (2007) 1305-1315
42. Shapiro G.I., and Harper J.W. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest. 104 (1999) 1645-1653
43. Singh S.V., Herman-Antosiewicz A., Singh A.V., Lew K.L., Srivastava S.K., Kamath R., Brown K.D., Zhang L., and Baskaran R. Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J. Biol. Chem. 279 (2004) 25813-25822
44. Sporn M.B., and Liby K.T. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat. Clin. Pract. Oncol. 2 (2005) 518-525
45. Srivastava S.K., and Singh S.V. Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis 25 (2004) 1701-1709
46. Thérien M. Synthesis of rofecoxib (MK 0966), Vioxx) 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone), a selective and orally active inhibitor of cyclooxygenase-2. Synthesis 12 (2001) 1778-1779
47. ® 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5h)-furanone), a selective and orally active inhibitor of cyclooxygenase-2. Synthesis 12 (2001) 1778-1779
48. Turner R.T., Evans G.L., Zhang M., Maran A., and Sibonga J.D. Is resveratrol an estrogen agonist in growing rats?. Endocrinology 140 (1999) 50-54
49. van Duursen M.B., Sanderson J.T., van der Bruggen M., van der Linden J., and van den Berg M. Effects of several dioxin-like compounds on estrogen metabolism in the malignant MCF-7 and nontumorigenic MCF-10A human mammary epithelial cell lines. Toxicol. Appl. Pharmacol. 190 (2003) 241-250
50. Visanji J.M., Duthie S.J., Pirie L., Thompson D.G., and Padfield P.J. Dietary isothiocyanates inhibit Caco-2 cell proliferation and induce G2/M phase cell cycle arrest, DNA damage, and G2/M checkpoint activation. J. Nutr. 134 (2004) 3121-3126
51. Xiao D., Pinto J.T., Gundersen G.G., and Weinstein I.B. Effects of a series of organosulfur compounds on mitotic arrest and induction of apoptosis in colon cancer cells. Mol. Cancer Ther. 4 (2005) 1388-1398
52. Xiao D., Vogel V., and Singh S.V. Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak. Mol. Cancer Ther. 5 (2006) 2931-2945
53. Yager J.D., and Davidson N.E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354 (2006) 270-282
54. Zoubine M.N., Weston A.P., Johnson D.C., Campbell D.R., and Banerjee S.K. 2-methoxyestradiol-induced growth suppression and lethality in estrogen-responsive MCF-7 cells may be mediated by down regulation of p34cdc2 and cyclin B1 expression. Int. J. Oncol. 15 (1999) 639-646